|
| 37503880 | High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience. | Neuro Oncol | 2024 |
| 38070781 | Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors. | Eur J Pharm Sci | 2024 |
| 35962595 | A high-dimensional mediation model for a neuroimaging mediator: Integrating clinical, neuroimaging, and neurocognitive data to mitigate late effects in pediatric cancer. | Biometrics | 2023 |
| 37664968 | Topotecan clearance based on a single sample and a population pharmacokinetic model: Application to a pediatric high-risk neuroblastoma clinical trial. | Pediatr Blood Cancer | 2023 |
| 37522896 | DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts. | Acta Neuropathol | 2023 |
| 38000061 | Application of the Rotterdam postoperative cerebellar mutism syndrome prediction model in patients undergoing surgery for medulloblastoma in a single institution. | J Neurosurg Pediatr | 2023 |
| 37823794 | Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients. | Clin Cancer Res | 2023 |
| 35652336 | Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. | Neuro Oncol | 2023 |
| 35789275 | Fastigial nuclei surgical damage and focal midbrain disruption implicate PAG survival circuits in cerebellar mutism syndrome. | Neuro Oncol | 2023 |
| 37043711 | Tackling Pediatric Low-Grade Gliomas: A Global Perspective. | JCO Glob Oncol | 2023 |
| 37343136 | Cerebellar mutism is linked to midbrain volatility and desynchronization from speech cortices. | Brain | 2023 |
| 37038335 | Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumors. | Neuro Oncol | 2023 |
| 37329245 | Social cognition and adjustment in adult survivors of pediatric central nervous system tumors. | Cancer | 2023 |
| 37126770 | Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 36548930 | Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. | J Clin Oncol | 2023 |
| 36808285 | Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. | Neuro Oncol | 2023 |
| 36641041 | Hypogonadism After Treatment for Medulloblastoma: Results From the SJMB03 Trial of Risk-Adapted Radiation Therapy. | Int J Radiat Oncol Biol Phys | 2023 |
| 36563909 | Endocrinopathy After Treatment for Medulloblastoma: Results From the SJMB03 Trial of Risk-Adapted Radiation Therapy. | Int J Radiat Oncol Biol Phys | 2023 |
| 34347089 | Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. | Neuro Oncol | 2022 |
| 35380295 | The posterior fossa syndrome questionnaire: using science to inform practice. | J Neurooncol | 2022 |
| 35733515 | Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. | Neurooncol Adv | 2022 |
| 35344053 | MRI sequences and interslice gap influence leptomeningeal metastasis detection in children with brain tumors. | Neuroradiology | 2022 |
| 35395680 | Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). | Neuro Oncol | 2022 |
| 35720861 | Reducing Wait Time in a High-volume Pediatric Neuro-oncology Clinic by Optimizing Process Flow: A Quality Improvement Project. | Pediatr Qual Saf | 2022 |
| 35664557 | Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. | Neurooncol Adv | 2022 |
| 36509072 | Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 36131015 | Unified rhombic lip origins of group 3 and group 4 medulloblastoma. | Nature | 2022 |
| 35982322 | Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials. | Acta Neuropathol | 2022 |
| 35286389 | Social Problem Solving in Survivors of Pediatric Brain Tumor. | J Pediatr Psychol | 2022 |
| 34850169 | Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study. | Neuro Oncol | 2022 |
| 35212779 | Population pharmacokinetics of crenolanib in children and young adults with brain tumors. | Cancer Chemother Pharmacol | 2022 |
| 34934181 | Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. | Lab Invest | 2022 |
| 34990779 | A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. | Int J Radiat Oncol Biol Phys | 2022 |
| 34894262 | Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. | Neuro Oncol | 2022 |
| 34643950 | Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. | Cancer | 2022 |
| 34714708 | Association Between Brain Substructure Dose and Cognitive Outcomes in Children With Medulloblastoma Treated on SJMB03: A Step Toward Substructure-Informed Planning. | J Clin Oncol | 2022 |
| 33259071 | Creation of a successful multidisciplinary course in pediatric neuro-oncology with a systematic approach to curriculum development. | Cancer | 2021 |
| 33743477 | Longitudinal associations between exposure to anesthesia and neurocognitive functioning in pediatric medulloblastoma. | Eur J Cancer | 2021 |
| 33823018 | Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. | Neuro Oncol | 2021 |
| 33737307 | Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. | Clin Cancer Res | 2021 |
| 33844469 | Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. | Pediatr Blood Cancer | 2021 |
| 33502920 | Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. | J Clin Oncol | 2021 |
| 34586478 | Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. | Cancer Chemother Pharmacol | 2021 |
| 34407349 | Lorlatinib in a Child with <i>ALK</i>-Fusion-Positive High-Grade Glioma. | N Engl J Med | 2021 |
| 34536944 | Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. | Eur J Cancer | 2021 |
| 34678152 | Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. | Cancer Cell | 2021 |
| 34215733 | Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. | Nat Commun | 2021 |
| 34125480 | Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. | Pediatr Blood Cancer | 2021 |
| 34292305 | Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group. | JAMA Oncol | 2021 |
| 34110925 | Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. | J Clin Oncol | 2021 |